(-)-Epigallocatechin-3-gallate interferes with mast cell adhesiveness, migration and its potential to recruit monocytes

Cellular and Molecular Life Sciences

Volumn 64, Issue 19-20, 2007, Pages 2690-2701

  Melgarejo, E ^a   Medina, M A ^a   Sanchez Jimenez F ^a   Botana, L M ^b   Dominguez M ^c   Escribano, L ^d   Orfao, A ^e   Urdiales, J L ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Adhesion; Chemokines; Integrin 5; Integrin 3; Mast cells; Monocyte chemoattractant protein 1

Indexed keywords

ALPHA5 INTEGRIN; BETA3 INTEGRIN; CHEMOKINE; CHEMOKINE MCP1; EPIGALLOCATECHIN GALLATE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL LINE; CELL MIGRATION; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HMC 1 CELL LINE; HUMAN; HUMAN CELL; MAST CELL; MONOCYTE; NUCLEOTIDE SEQUENCE;

ANTINEOPLASTIC AGENTS; CATECHIN; CELL ADHESION; CELL LINE; CELL MOVEMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTEGRINS; MAST CELLS; MONOCYTES; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 35649001431     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-7331-4     Document Type: Article

References (47)

1. Norrby, K. (2002) Mast cells and angiogenesis. APMIS 110, 355-371.
2. Metcalfe, D. D., Baram, D. and Mekori, Y. A. (1997) Mast cells. Physiol. Rev. 77, 1033-1079.
3. Ribatti, D., Crivellato, E., Roccaro, A. M., Ria, R. and Vacca, A. (2004) Mast cell contribution to angiogenesis related to tumour progression. Clin. Exp. Allergy 34, 1660-1664.
4. García-Montero, A. C., Jara-Acevedo, M., Teodosio, C., Sánchez, M. L., Núñez, R., Prados, A., Aldanondo, I., Sánchez, L., Domínguez, M., Botana, L. M., Sánchez- Jiménez, F., Sotlar, K., Almeida, J., Escribano, L. and Orfao, A. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108, 2366-2372.
5. Sánchez-Jiménez, F., Montañez, R., Correa-Fiz, F., Chaves, P., Rodríguez-Caso, C., Urdiales, J. L., Aldana, J. F. and Medina, M. A. (2007) The usefulness of post-genomics tools for characterization of the amine cross-talk in mammalian cells. Biochem. Soc. Trans. 35, 381-385.
6. Tosetti, F., Ferrari, N., De Flora, S. and Albini, A. (2002) Angioprevention: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J. 16, 2-14.
7. Hofmann, C. S. and Sonenshein, G. E. (2003) Green tea polyphenol epigallocatechin-3 gallate induces apoptosis of proliferating vascular smooth muscle cells via activation of p53. FASEB J. 17, 702-704.
8. Nihal, M., Ahmad, N., Mukhtar, H. and Wood, G. S. (2005) Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int. J. Cancer 114, 513-521.
9. Sah, J. F., Balasubramanian, S., Eckert, R. L. and Rorke, E. A. (2004) Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J. Biol. Chem. 279, 12755-12762.
10. Sachinidis, A., Seul, C., Seewald, S., Ahn, H., Ko, Y. and Vetter, H. (2000) Green tea compounds inhibit tyrosine phosphorylation of PDGF beta-receptor and transformation of A172 human glioblastoma. FEBS Lett. 471, 51-55.
11. Liu, J. D., Chen, S. H., Lin, C. L., Tsai, S. H. and Liang, Y. C. (2001) Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. J. Cell. Biochem. 83, 631-642.
12. Suzuki, Y. and Isemura, M. (2001) Inhibitory effect of epigallocatechin gallate on adhesion of murine melanoma cells to laminin. Cancer Lett. 173, 15-20.
13. Benelli, R., Vene, R., Bisacchi, D., Garbisa, S. and Albini, A. (2002) Anti-invasive effects of green tea polyphenol epigallocatechin-3-gallate (EGCG), a natural inhibitor of metallo and serine proteases. Biol. Chem. 383, 101-105.
14. Mittal, A., Pate, M. S., Wylie, R. C., Tollefsbol, T. O. and Katiyar, S. K. (2004) EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int. J. Oncol. 24, 703-710.
15. Fang, M. Z., Wang, Y., Ai, N., Hou, Z., Sun, Y., Lu, H., Welsh, W. and Yang, C. S. (2003) Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 63, 7563-7570.
16. Baliga, M. S., Meleth, S. and Katiyar, S. K. (2005) Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin. Cancer Res. 11, 1918-1927.
17. Fassina, G., Vene, R., Morini, M., Minghelli, S., Benelli, R., Noonan, D. M. and Albini, A. (2004) Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin. Cancer Res. 10, 4865-4873.
18. Kondo, T., Ohta, T., Igura, K., Hara, Y. and Kaji, K. (2002) Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett. 180, 139-144.
19. Lai, H. C., Chao, W. T., Chen, Y. T. and Yang, V. C. (2004) Effect of EGCG, a major component of green tea, on the expression of Ets-1, c-Fos, and c-Jun during angiogenesis in vitro. Cancer Lett. 213, 181-188.
20. Lamy, S., Gingras, D. and Beliveau, R. (2002) Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 62, 381-385.
21. Singh, A. K., Seth, P., Anthony, P., Husain, M. M., Madhavan, S., Mukhtar, H. and Maheshwari, R. K. (2002) Green tea constituent epigallocatechin-3-gallate inhibits angiogenic differentiation of human endothelial cells. Arch. Biochem. Biophys. 401, 29-37.
22. Yamakawa, S., Asai, T., Uchida, T., Matsukawa, M., Akizawa, T. and Oku, N. (2004) (-)-Epigallocatechin gallate inhibits membrane-type 1 matrix metalloproteinase, MT1-MMP, and tumor angiogenesis. Cancer Lett. 210, 47-55.
23. Donnelly, L. E. and Rogers, D. F. (2003) Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 63, 1973-1998.
24. Rodríguez-Caso, C., Rodríguez-Agudo, D., Sánchez-Jiménez, F. and Medina, M. A. (2003) Green tea epigallocatechin-3-gallate is an inhibitor of mammalian histidine decarboxylase. Cell. Mol. Life Sci. 60, 1760-1763.
25. Dona, M., Dell-Aica, I., Calabrese, F., Benelli, R., Morini, M., Albini, A. and Garbisa, S. (2003) Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J. Immunol. 170, 4335-4341.
26. Ludwig, A., Lorenz, M., Grimbo, N., Steinle, F., Meiners, S., Bartsch, C., Stangl, K., Baumann, G. and Stangl, V. (2004) The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem. Biophys. Res. Commun. 316, 659-665.
27. Shin, H. Y., Kim, S. H., Jeong, H. J., Kim, S. Y., Shin, T. Y., Um, J. Y., Hong, S. H. and Kim, H. M. (2007) Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. Int. Arch. Allergy Immunol. 142, 335-344.
28. Urdiales, J. L., Becker, E., Andrieu, M., Thomas, A., Jullien, J., van Grunsven, L. A., Menut, S., Evan, G. I., Martin-Zanca, D. and Rudkin, B. B. (1998) Cell cycle phase-specific surface expression of nerve growth factor receptors TrkA and p75(NTR). J. Neurosci. 18, 6767-6775.
29. Valent, P., Schernthaner, G. H., Sperr, W. R., Fritsch, G., Agis, H., Willheim, M., Bhring, H. J., Orfao, A. and Escribano, L. (2001) Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol. Rev. 179, 74-81.
30. Luscinskas, F.W. and Lawler, J. (1994) Integrins as dynamic regulators of vascular function. FASEB J. 8, 929-938.
31. Brooks, P. C., Clark, R. A. and Cheresh, D. A. (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264, 569-571.
32. Hynes, R. O. (2002)Areevaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918-921.
33. George, E. L., Georges-Labouesse, E. N., Patel-King, R. S., Rayburn, H. and Hynes, R. O. (1993) Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119, 1079-1091.
34. Kim, S., Bell, K., Mousa, S. A. and Varner, J. A. (2000) Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am. J. Pathol. 156, 1345-1362.
35. Yang, J. T., Rayburn, H. and Hynes, R. O. (1993) Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119, 1093-1105.
36. Conti, P. and DiGioacchino, M. (2001) MCP-1 and RANTES are mediators of acute and chronic inflammation. Allergy Asthma Proc. 22, 133-137.
37. Hung, C. F., Huang, T. F., Chiang, H. S. andWu, W. B. (2005) (-)-Epigallocatechin-3-gallate, a polyphenolic compound from green tea, inhibits fibroblast adhesion and migration through multiple mechanisms. J. Cell. Biochem. 96, 183-197.
38. Hong, M. H., Kim, M. H., Chang, H. J., Kim, N. H., Shin, B. A., Ahn, B. W., and Jung, Y. D. (2007) (-)-Epigallocatechin-3-gallate inhibits monocyte chemotactic protein-1 expression in endothelial cells via blocking NF-kappaB signaling. Life Sci. 80, 1957-1965.
39. Selvan, R. S., Butterfield, J. H. and Krangel, M. S. (1994) Expression of multiple chemokine genes by a human mast cell leukemia. J. Biol. Chem. 269, 13893-13898.
40. Jiang, Y., Valente, A. J., Williamson, M. J., Zhang, L. and Graves, D. T. (1990) Post-translational modification of a monocyte-specific chemoattractant synthesized by glioma, osteosarcoma, and vascular smooth muscle cells. J. Biol. Chem. 265, 18318-18321.
41. Negus, R. P., Stamp, G. W., Relf, M. G., Burke, F., Malik, S. T., Bernasconi, S., Allavena, P., Sozzani, S., Mantovani, A. and Balkwill, F. R. (1995) The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J. Clin. Invest. 95, 2391-2396.
42. Ueno, T., Toi, M., Saji, H., Muta, M., Bando, H., Kuroi, K., Koike, M., Inadera, H. and Matsushima, K. (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6, 3282-3289.
43. Kuroda, T., Kitadai, Y., Tanaka, S., Yang, X., Mukaida, N., Yoshihara, M. and Chayama, K. (2005) Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin. Cancer Res. 11, 7629-7636.
44. Boisvert, W. A. (2004) Modulation of atherogenesis by chemokines. Trends Cardiovasc. Med. 14, 161-165.
45. Metcalfe, D. D. and Akin, C. (2001) Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk. Res. 25, 577-582.
46. Marone, G., Spadaro, G., Granata, F. and Triggiani, M. (2001) Treatment of mastocytosis: Pharmacologic basis and current concepts. Leuk. Res. 25, 583-594.
47. Núñez-López, R., Escribano, L., Schernthaner, G. H., Prados, A., Rodríguez-González, R., Díaz-Agustín, B., López, A., Hauswirth, A., Valent, P., Almeida, J., Bravo, P. and Orfao, A. (2003) Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis. Br. J. Haematol. 120, 257-265.